Loading
Cleerly
Cleerly is a digital healthcare technology company based in Denver, founded in 2017. The company offers a non-invasive, AI-driven platform designed to quantify and characterize plaque buildup in coronary arteries. Cleerly aims to enhance the identification of at-risk patients, ultimately working towards the elimination of heart attacks through early treatment and prevention. The core product is an FDA-cleared digital care platform that analyzes coronary computed tomography angiography (CCTA) studies. It utilizes proprietary machine learning algorithms to measure atherosclerosis, detect arterial narrowing, and assess the likelihood of reduced blood flow. Cleerly's solutions support clinical decision-making by improving heart attack risk assessments and enabling personalized treatment plans for patients. The company primarily serves healthcare providers and stakeholders in the coronary care pathway, focusing on enhancing health literacy and delivering detailed insights for effective diagnosis and treatment of heart disease.
Funding
Every round, secondary, debt facility or acquisition involving Cleerly that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$40M